At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 69 enrolled
Drug / intervention
Docetaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Gemcitabine, and 1 other intervention for Non-Small Cell Lung Cancer (NSCLC). Completed, enrolled 69 participants across 1 site.
Detailed Summary
A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer (NSCLC)
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionNov 2016
TodayJul 2026
First PostedSep 26, 2013
Enrollment StartSep 11, 2013
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.8 years ago
Interventions
Docetaxeldrug
Powder for solution for infusion
Gemcitabinedrug
Powder for solution for infusion
Lurbinectedin (PM01183)drug
Powder for concentrate for solution for infusion